We sought to evaluate the association between plasma levels of monocyte chemoattractant protein(MCP)-1 and the risk for subclinical atherosclerosis. Monocyte chemoattractant protein is a chemokine that recruits monocy...We sought to evaluate the association between plasma levels of monocyte chemoattractant protein(MCP)-1 and the risk for subclinical atherosclerosis. Monocyte chemoattractant protein is a chemokine that recruits monocytes into the developing atheroma and may contribute to atherosclerotic disease development and progression. Plasma levels of MCP-1 are independently associated with prognosis in patients with acute coronary syndromes, but few population-based data are available from subjects in earlier stages of atherosclerosis. In the Dallas Heart Study, a population-based probability sample of adults in Dallas County ≤65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with traditional cardiovascular risk factors, high-sensitivity C-reactive protein(hs-CRP), and coronary artery calcium(CAC) measured by electron beam computed tomography. Higher MCP-1 levels were associated with older age, white race, family history of premature coronary disease, smoking, hypertension, diabetes, hypercholesterolemia,and higher levels of hs-CRP (p< 0.01 for each). Similar associations were observed between MCP-1 and risk factors in the subgroup of participants without detectable CAC. Compared with the subjects in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score ≥10) for subjects in the second, third, and fourth quartiles were 1.30 (95%confidence interval 0.99 to 1.73), 1.60 (95%CI 1.22 to 2.11), and 2.02 (95%CI 1.54 to 2.63), respectively. The association between MCP-1 and CAC remained significant when adjusted for traditional cardiovascular risk factors, but not when further adjusted for age. In a large population-based sample, plasma levels of MCP-1 were associated with traditional risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of the atherogenic effects of these risk factors. These findings support the potential role of MCP-1 as a biomarker target for drug development.展开更多
OBJECTIVES: This study sought to determine whether there are race and gender differences in the distribution of C-reactive protein(CRP) levels. BACKGROUND: Few data are available comparing CRP distributions in differe...OBJECTIVES: This study sought to determine whether there are race and gender differences in the distribution of C-reactive protein(CRP) levels. BACKGROUND: Few data are available comparing CRP distributions in different race and gender groups. Recent clinical practice recommendations for CRP testing for cardiovascular risk assessment suggest a uniform threshold to define high relative risk( >3 mg/l). METHODS: We measured CRP in 2,749 white and black subjects ages 30 to 65 participating in the Dallas Heart Study, a multiethnic, population-based, probability sample, and compared levels of CRP between different race and gender groups. RESULTS: Black subjects had higher CRP levels than white subjects(median, 3.0 vs. 2.3 mg/l; p< 0.001) and women had higher CRP levels than men(median, 3.3 vs. 1.8 mg/l; p< 0.001). The sample-weight adjusted proportion of subjects with CRP levels >3 mg/l was 31%, 40%, 51%, and 58%in white men, black men, white women, and black women, respectively(p< 0.05 for each group vs. white men). After adjustment for traditional cardiovascular risk factors, estrogen and statin use, and body mass index, a CRP level >3 mg/l remained more common in white women(odds ratio[OR] 1.6; 95%confidence interval[CI] 1.1 to 2.5) and black women(OR 1.7; 95%CI 1.2 to 2.6) but not in black men(OR, 1.3; 95%CI, 0.8 to 1.9) when compared with white men. CONCLUSIONS: Significant race and gender differences exist in the population distribution of CRP. Further research is needed to determine whether race and gender differences in CRP levels contribute to differences in cardiovascular outcomes, and whether thresholds for cardiovascular risk assessment should be adjusted for different race and gender groups.展开更多
文摘We sought to evaluate the association between plasma levels of monocyte chemoattractant protein(MCP)-1 and the risk for subclinical atherosclerosis. Monocyte chemoattractant protein is a chemokine that recruits monocytes into the developing atheroma and may contribute to atherosclerotic disease development and progression. Plasma levels of MCP-1 are independently associated with prognosis in patients with acute coronary syndromes, but few population-based data are available from subjects in earlier stages of atherosclerosis. In the Dallas Heart Study, a population-based probability sample of adults in Dallas County ≤65 years old, plasma levels of MCP-1 were measured in 3,499 subjects and correlated with traditional cardiovascular risk factors, high-sensitivity C-reactive protein(hs-CRP), and coronary artery calcium(CAC) measured by electron beam computed tomography. Higher MCP-1 levels were associated with older age, white race, family history of premature coronary disease, smoking, hypertension, diabetes, hypercholesterolemia,and higher levels of hs-CRP (p< 0.01 for each). Similar associations were observed between MCP-1 and risk factors in the subgroup of participants without detectable CAC. Compared with the subjects in the lowest quartile of MCP-1, the odds of prevalent CAC (CAC score ≥10) for subjects in the second, third, and fourth quartiles were 1.30 (95%confidence interval 0.99 to 1.73), 1.60 (95%CI 1.22 to 2.11), and 2.02 (95%CI 1.54 to 2.63), respectively. The association between MCP-1 and CAC remained significant when adjusted for traditional cardiovascular risk factors, but not when further adjusted for age. In a large population-based sample, plasma levels of MCP-1 were associated with traditional risk factors for atherosclerosis, supporting the hypothesis that MCP-1 may mediate some of the atherogenic effects of these risk factors. These findings support the potential role of MCP-1 as a biomarker target for drug development.
文摘OBJECTIVES: This study sought to determine whether there are race and gender differences in the distribution of C-reactive protein(CRP) levels. BACKGROUND: Few data are available comparing CRP distributions in different race and gender groups. Recent clinical practice recommendations for CRP testing for cardiovascular risk assessment suggest a uniform threshold to define high relative risk( >3 mg/l). METHODS: We measured CRP in 2,749 white and black subjects ages 30 to 65 participating in the Dallas Heart Study, a multiethnic, population-based, probability sample, and compared levels of CRP between different race and gender groups. RESULTS: Black subjects had higher CRP levels than white subjects(median, 3.0 vs. 2.3 mg/l; p< 0.001) and women had higher CRP levels than men(median, 3.3 vs. 1.8 mg/l; p< 0.001). The sample-weight adjusted proportion of subjects with CRP levels >3 mg/l was 31%, 40%, 51%, and 58%in white men, black men, white women, and black women, respectively(p< 0.05 for each group vs. white men). After adjustment for traditional cardiovascular risk factors, estrogen and statin use, and body mass index, a CRP level >3 mg/l remained more common in white women(odds ratio[OR] 1.6; 95%confidence interval[CI] 1.1 to 2.5) and black women(OR 1.7; 95%CI 1.2 to 2.6) but not in black men(OR, 1.3; 95%CI, 0.8 to 1.9) when compared with white men. CONCLUSIONS: Significant race and gender differences exist in the population distribution of CRP. Further research is needed to determine whether race and gender differences in CRP levels contribute to differences in cardiovascular outcomes, and whether thresholds for cardiovascular risk assessment should be adjusted for different race and gender groups.
